Ultragenyx Pharmaceutical (RARE) News Today $28.13 -0.98 (-3.37%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$28.37 +0.24 (+0.85%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Ultragenyx Pharmaceutical Inc. Grants Restricted Stock Units to New Non-Executive OfficersSeptember 19 at 4:50 PM | quiverquant.comQUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 19 at 4:30 PM | globenewswire.comRep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) SharesSeptember 17 at 5:08 PM | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 17 at 4:30 AM | marketbeat.comIs Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity?September 16, 2025 | insidermonkey.comGreat Lakes Advisors LLC Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 15, 2025 | marketbeat.comMillennium Management LLC Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 14, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) EVP Karah Herdman Parschauer Sells 2,450 SharesSeptember 13, 2025 | insidertrades.comHC Wainwright Reiterates "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)September 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Fred Alger Management LLCSeptember 11, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comCantor Fitzgerald Remains a Buy on Ultragenyx Pharmaceutical (RARE)September 9, 2025 | theglobeandmail.comUltragenyx Reports Positive Phase 3 Gene Therapy ResultsSeptember 9, 2025 | msn.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Alliancebernstein L.P.September 9, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. Reports Positive Phase 3 Results for DTX401 Gene Therapy in Glycogen Storage Disease Type Ia with Significant Reductions in Cornstarch Intake and Improved Glycemic ControlSeptember 8, 2025 | quiverquant.comQUltragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)September 8, 2025 | globenewswire.comParkman Healthcare Partners LLC Has $11.02 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 8, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Cinctive Capital Management LPSeptember 7, 2025 | marketbeat.comCubist Systematic Strategies LLC Makes New Investment in Ultragenyx Pharmaceutical Inc. $RARESeptember 7, 2025 | marketbeat.comEFG Asset Management North America Corp. Lowers Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 6, 2025 | marketbeat.comCutter Capital Management LP Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 6, 2025 | marketbeat.comAlyeska Investment Group L.P. Grows Position in Ultragenyx Pharmaceutical Inc. $RARESeptember 6, 2025 | marketbeat.comAssessing Ultragenyx Pharmaceutical: Insights From 8 Financial AnalystsSeptember 6, 2025 | benzinga.comAdage Capital Partners GP L.L.C. Has $77.82 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 5, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 6.5% - Still a Buy?September 4, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.comFirst Light Asset Management LLC Cuts Position in Ultragenyx Pharmaceutical Inc. $RARESeptember 4, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comPDT Partners LLC Increases Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARESeptember 3, 2025 | prnewswire.comGraham Capital Management L.P. Increases Position in Ultragenyx Pharmaceutical Inc. $RARESeptember 3, 2025 | marketbeat.comNorthern Trust Corp Has $20.58 Million Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 3, 2025 | marketbeat.comB. Metzler seel. Sohn & Co. AG Purchases 14,581 Shares of Ultragenyx Pharmaceutical Inc. $RARESeptember 2, 2025 | marketbeat.comDriehaus Capital Management LLC Increases Stock Position in Ultragenyx Pharmaceutical Inc. $RARESeptember 1, 2025 | marketbeat.comTrexquant Investment LP Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 1, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Rafferty Asset Management LLCSeptember 1, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Acquired by Walleye Capital LLCSeptember 1, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Stake Decreased by Jump Financial LLCSeptember 1, 2025 | marketbeat.comUltragenyx to Participate at Investor Conferences in SeptemberAugust 29, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 29, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. $RARE Shares Acquired by Capital Fund Management S.A.August 28, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 27, 2025 | prnewswire.comUltragenyx Pharmaceutical Inc. $RARE Shares Acquired by Price T Rowe Associates Inc. MDAugust 27, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 25, 2025 | globenewswire.comRussell Investments Group Ltd. Acquires 34,635 Shares of Ultragenyx Pharmaceutical Inc. $RAREAugust 25, 2025 | marketbeat.comUltragenyx Pharmaceutical (RARE) Valuation Spotlight as DTX401 Gene Therapy Advances With FDA SubmissionAugust 24, 2025 | finance.yahoo.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 24, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Charles Schwab Investment Management Inc.August 24, 2025 | marketbeat.comCandriam S.C.A. Purchases 53,760 Shares of Ultragenyx Pharmaceutical Inc. $RAREAugust 23, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREAugust 22, 2025 | prnewswire.com Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼0.940.79▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼910▲RARE Articles Average Week Get the Latest News and Ratings for RARE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Ultragenyx Pharmaceutical and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies QIAGEN News BridgeBio Pharma News Roivant Sciences News Moderna News Elanco Animal Health News Verona Pharma PLC American Depositary Share News Revolution Medicines News Grifols News Abivax News Rhythm Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
